Zejula and Hypothyroidism - a phase IV clinical study of FDA data

Summary:

Hypothyroidism is reported as a side effect among people who take Zejula (niraparib tosylate), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Lipitor, and have Ovarian cancer.

The phase IV clinical study analyzes which people have Hypothyroidism when taking Zejula. It is created by eHealthMe based on reports of 22,010 people who have side effects when taking Zejula from the FDA, and is updated regularly.

What is Zejula?

Zejula has active ingredients of niraparib tosylate. eHealthMe is studying from 22,014 Zejula users. Check the latest studies of Zejula.

What is Hypothyroidism?

Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development) is found to be associated with 1,615 drugs and 2,599 conditions by eHealthMe. Check the latest studies of Hypothyroidism.

On Jul, 16, 2026

22,010 people reported to have side effects when taking Zejula.
Among them, 41 people (0.19%) have Hypothyroidism.

Among these 41 people:

How long have people been on Zejula when they have Hypothyroidism? *

What is the gender of people who have Hypothyroidism when taking Zejula? *

female: 100 %
male: 0.0 %

What is the age of people who have Hypothyroidism when taking Zejula? *

What are other drugs people take besides Zejula? *

What are other side effects people have besides Hypothyroidism? *

Nausea (feeling of having an urge to vomit): 27 people, 65.85%
Fatigue (feeling of tiredness): 24 people, 58.54%
Weakness: 18 people, 43.90%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 17 people, 41.46%
High Blood Pressure: 16 people, 39.02%
Headache (pain in head): 16 people, 39.02%
Constipation: 16 people, 39.02%
Pain: 14 people, 34.15%
Joint Pain: 13 people, 31.71%
Thrombocytopenia (decrease of platelets in blood): 13 people, 31.71%

What are the existing conditions these people have? *

Ovarian Cancer (cancer of ovary): 26 people, 63.41%
Malignant Peritoneal Neoplasm (cancer tumour of peritoneum): 11 people, 26.83%
Malignant Neoplasm Of Uterine Adnexa (cancer tumour of uterus surrounding ,ovaries ,fallopian tubes ,ligaments): 4 people, 9.76%
Diabetes: 2 people, 4.88%
Fallopian Tube Cancer (cancer of fallopian tube): 2 people, 4.88%
Nausea (feeling of having an urge to vomit): 2 people, 4.88%
Stress And Anxiety: 2 people, 4.88%
Heart Palpitations (feelings or sensations that your heart is pounding or racing): 1 person, 2.44%
Depression: 1 person, 2.44%
Fever: 1 person, 2.44%

* Approximation only. Some reports may have incomplete information.

Do you take Zejula and have Hypothyroidism?

- Check whether Hypothyroidism is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zejula:

Zejula (22,014 reports)

Hypothyroidism treatments and more:

Hypothyroidism (168,065 reports)

Browse all side effects of Zejula:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hypothyroidism:

Hypothyroidism (1,615 drugs)

Browse all the conditions that are associated with Hypothyroidism:

Hypothyroidism (2,599 conditions)

Related publications that referenced our studies

Ezeji GC, Inoue T, Bahtiyar G, Sacerdote A, "Hallucinations associated with miglitol use in a patient with chronic kidney disease and hypothyroidism", BMJ case reports, 2015 Feb .
Ezeji GC, Inoue T, Bahtiyar G, Sacerdote A, "Hallucinations associated with miglitol use in a patient with chronic kidney disease and hypothyroidism", BMJ case reports, 2015 Feb .

How the study uses the data?

The study uses data from the FDA. It is based on niraparib tosylate (the active ingredients of Zejula) and Zejula (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.